MicroRNAs networks in thyroid cancers: Focus on miRNAs related to the fascin

Journal of Diabetes and Metabolic Disorders

Volumn 12, Issue 1, 2013, Pages

  Samimi, Hilda ^a,b   Zaki dizaji, Majid ^b,c   Ghadami, Mohsen ^b,c   Shahzadeh fazeli, Abolhasan ^a   Khashayar, Patricia ^b   Soleimani, Masoud ^d   Larijani, Bagher ^b   Haghpanah, Vahid ^b  

^a Science and culture University   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Fascin; microRNA; Oncomir; Thyroid Cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; B RAF KINASE; FASCIN; MICRORNA; MICRORNA 15A; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 101; MICRORNA 10B; MICRORNA 133A; MICRORNA 133B; MICRORNA 145; MICRORNA 146A; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 17; MICRORNA 200; MICRORNA 206; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 24; MICRORNA 29; MICRORNA 290; MICRORNA 34; MICRORNA 34A; MICRORNA 519; MICRORNA 92; MICRORNA LET 7; MICRORNA LET 7F; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CARCINOGENESIS; GENE MUTATION; GENE REARRANGEMENT; GENOMIC INSTABILITY; HUMAN; METASTASIS; NONHUMAN; ONCOGENE RAS; ONCOGENE RET; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR ESCAPE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; AGING CONTROL; ANGIOGENESIS; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC STABILITY; IMMORTALITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INTRON; METASTASIS INHIBITION; MIRNA GENE; PAPILLARY CARCINOMA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TUMOR INVASION; UPREGULATION; X CHROMOSOME;

EID: 84882577307     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-12-31     Document Type: Review

References (47)

1. Cobin R, Gharib H, Bergman D, Clark O, Cooper D, Daniels G, Dickey R, Duick D, Garber J, Hay I. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2001, 7:202.
2. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi A, Tavangar S, Malekzadeh R, Larijani B. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer 2006, 43:80. 10.4103/0019-509X.25889, 16790945.
3. Larijani B, Shirzad M, Mohagheghi M, Haghpanah V, Mosavi-Jarrahi A, Tavangar S, Vassigh A, Hossein-Nezhad A, Bandarian F, Baradar-Jalili R. Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR). Asian Pac J Cancer Prev 2004, 5:36-39.
4. Glattre E, Haldorsen T. Positive correlation between parity and incidence of thyroid cancer: new evidence based on complete Norwegian birth cohorts. Int J Cancer 1991, 49:831-836. 10.1002/ijc.2910490606, 1959987.
5. Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 1999, 8:991-997.
6. Amoli MM, Yazdani N, Amiri P, Sayahzadeh F, Haghpanah V, Tavangar SM, Amirzargar A, Ghaffari H, Nikbin B, Larijani B. HLA-DR association in papillary thyroid carcinoma. Dis Markers 2010, 28:49-53. 10.1155/2010/130276, 20164547.
7. Maso LD, Vecchia CL, Franceschi S, Preston-Martin S, Ron E, Levi F, Mack W, Mark SD, McTiernan A, Kolonel L. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 2000, 11:137-144. 10.1023/A:1008938520101, 10710197.
8. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi M-T, Larijani B, Mostaan LV. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 2012, 208:100-103. 10.1016/j.prp.2011.12.009, 22293278.
9. Spitz MR, Sider JG, Katz RL, Pollack ES, Newell GR. Ethnic patterns of thyroid cancer incidence in the United States, 1973-1981. Int J Cancer 1988, 42:549-553. 10.1002/ijc.2910420413, 3170027.
10. Laurberg P, Nøhr S, Pedersen K, Hreidarsson A, Andersen S, Pedersen IB, Knudsen N, Perrild H, Jørgensen T, Ovesen L. Thyroid disorders in mild iodine deficiency. Thyroid 2000, 10:951-963. 10.1089/thy.2000.10.951, 11128722.
11. Williams E, Doniach I, Bjarnason O, Michie W. Thyroid cancer in an iodide rich area. A histopathological study. Cancer 1977, 39:215-222. 10.1002/1097-0142(197701)39:1<215::AID-CNCR2820390134>3.0.CO;2-#, 832237.
12. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167. 10.1001/jama.295.18.2164, 16684987.
13. Roth LM. Tumors of the thyroid gland. Am J Surg Pathol 1993, 17:1196.
14. Büssing I, Slack FJ, Großhans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008, 14:400. 10.1016/j.molmed.2008.07.001, 18674967.
15. Hwang H, Mendell J. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94:776-780. 10.1038/sj.bjc.6603023, 2361377, 16495913.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
17. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005, 37:766-770. 10.1038/ng1590, 15965474.
18. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005, 33:2697-2706. 10.1093/nar/gki567, 1110742, 15891114.
19. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
21. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Seminars in cancer biology. 27-30 October 2008 2008, 79-88. California: Elsevier.
22. Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011, 12:319-321. 10.1016/S1470-2045(11)70067-5, 21463831.
23. Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. AAPS J 2010, 12:309-317. 10.1208/s12248-010-9194-0, 2895440, 20422339.
24. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009, 285:116-126. 10.1016/j.canlet.2009.04.031, 19464788.
25. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urologic oncology: seminars and original investigations. 30January-2February 2010 2010, 4-13. New York: Elsevier.
26. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 MicroRNA family. Cell 2005, 120:635-647. 10.1016/j.cell.2005.01.014, 15766527.
27. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005, 102:18081. 10.1073/pnas.0506216102, 1312381, 16330772.
28. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM. MicroRNAs (miR)-221 and miR-222, both over expressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007, 14:791-798. 10.1677/ERC-07-0129, 17914108.
29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944. 10.1073/pnas.0506654102, 1236577, 16166262.
30. Voorhoeve PM, Agami R. Classifying microRNAs in cancer: the good, the bad and the ugly. Biochimica et Biophysica Acta (BBA)-Reviews on, Cancer 2007, 1775:274-282.
31. Wiemer EAC. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007, 43:1529-1544. 10.1016/j.ejca.2007.04.002, 17531469.
32. Montano M. MicroRNAs: miRRORS of health and disease. Translational research: the journal of laboratory and clinical medicine 2011, 157:157.
33. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12. 10.1016/j.ydbio.2006.08.028, 16989803.
34. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005, 353:1768-1771. 10.1056/NEJMp058190, 16251533.
35. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metabol 2008, 93:1600.
36. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu C, Franssila K, Suster S. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102:19075. 10.1073/pnas.0509603102, 1323209, 16365291.
37. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri M, Troncone G, Chiappetta G, Liu C, Santoro M, Negrini M. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006, 13:497-508. 10.1677/erc.1.01209, 16728577.
38. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA, Baloch ZW. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007, 18:163-173. 10.1007/s12022-007-0023-7, 18058265.
39. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E. Specific microRNAs are down regulated in human thyroid anaplastic carcinomas. Oncogene 2007, 26:7590-7595. 10.1038/sj.onc.1210564, 17563749.
40. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metabol 2006, 91:3584.
41. Bullock MD, Sayan AE, Packham GK, Mirnezami AH. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 2012, 91:3-12.
42. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009, 23:2140-2151. 10.1101/gad.1820209, 2751985, 19759262.
43. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914. 10.1074/jbc.C800074200, 3258899, 18411277.
44. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011, 13:317-323. 10.1038/ncb2173, 3075845, 21336307.
45. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004, 16:590-596. 10.1016/j.ceb.2004.07.009, 15363811.
46. Chen G, Zhang FR, Ren J, Tao LH, Shen ZY, Lv Z, Yu SJ, Dong BF, Xu LY, Li EM. Expression of fascin in thyroid neoplasms: a novel diagnostic marker. J Cancer Res Clin Oncol 2008, 134:947-951. 10.1007/s00432-008-0374-6, 18343949.
47. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009, 69:1279-1283. 10.1158/0008-5472.CAN-08-3559, 2754225, 19190326.